Oral immunotherapy for Helicobacter pylori: Can it be trusted? A systematic review

IF 4.3 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Helicobacter Pub Date : 2024-03-21 DOI:10.1111/hel.13067

Mohammad Hossein Peypar, Amin Vesal Yeganeh, Ali Ramazani, Arman Alizadeh, Mahdi Abdorrashidi, Amirmohammad Tohidinia, Mohammad Mahdi Shamlou, Mohammad Heiat

{"title":"Oral immunotherapy for Helicobacter pylori: Can it be trusted? A systematic review","authors":"Mohammad Hossein Peypar, Amin Vesal Yeganeh, Ali Ramazani, Arman Alizadeh, Mahdi Abdorrashidi, Amirmohammad Tohidinia, Mohammad Mahdi Shamlou, Mohammad Heiat","doi":"10.1111/hel.13067","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p><i>Helicobacter pylori</i> (<i>H. pylori</i>) is a rod-shaped, gram-negative, microaerophilic bacterium that can be identified by gram staining. Its relationship with cancer is significant since it is involved in approximately 80% of gastric cancers and 5.5% of all malignant cancers. Two lines of treatment have been defined for <i>H. pylori</i>, but almost 40% of patients do not respond to the first line. Recent trials have investigated oral Immunotherapy as a new treatment method. The aim of this systematic review was to investigate the potential effects of oral Immunotherapy on eradication rate of <i>H. pylori</i> in human studies.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The systematic review was performed according to PRISMA guidelines. We searched online databases, including Scopus, PubMed, and Web of Science (ISI). Our search strategy was limited to English articles and studies on human populations that use oral immunotherapy for <i>H. pylori</i>.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The total number of primary research records in different databases was 2775. After removing duplicate articles (<i>n</i> = 870), we excluded 1829 for reasons including non-human studies, irrelevance to our study objective, non-English language, or lack of information. Of the remaining 76 articles, only seven had sufficient information, and the rest were excluded. The studies were divided into two groups: those that used bovine antibody and those that used immunoglobulin Y to eradicate <i>H. pylori</i>.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In the group of Immunoglobulin Y, three out of four studies suggest that using Immunoglobulin Y for the treatment of <i>H. pylori</i> infection is significant. However, the group using bovine antibody for the treatment of <i>H. pylori</i> infection has various results, as two out of three studies concluded that bovine antibody therapy is not significant.</p>\n </section>\n </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 2","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Helicobacter","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hel.13067","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Helicobacter pylori (H. pylori) is a rod-shaped, gram-negative, microaerophilic bacterium that can be identified by gram staining. Its relationship with cancer is significant since it is involved in approximately 80% of gastric cancers and 5.5% of all malignant cancers. Two lines of treatment have been defined for H. pylori, but almost 40% of patients do not respond to the first line. Recent trials have investigated oral Immunotherapy as a new treatment method. The aim of this systematic review was to investigate the potential effects of oral Immunotherapy on eradication rate of H. pylori in human studies.

Methods

The systematic review was performed according to PRISMA guidelines. We searched online databases, including Scopus, PubMed, and Web of Science (ISI). Our search strategy was limited to English articles and studies on human populations that use oral immunotherapy for H. pylori.

Results

The total number of primary research records in different databases was 2775. After removing duplicate articles (n = 870), we excluded 1829 for reasons including non-human studies, irrelevance to our study objective, non-English language, or lack of information. Of the remaining 76 articles, only seven had sufficient information, and the rest were excluded. The studies were divided into two groups: those that used bovine antibody and those that used immunoglobulin Y to eradicate H. pylori.

Conclusion

In the group of Immunoglobulin Y, three out of four studies suggest that using Immunoglobulin Y for the treatment of H. pylori infection is significant. However, the group using bovine antibody for the treatment of H. pylori infection has various results, as two out of three studies concluded that bovine antibody therapy is not significant.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

幽门螺旋杆菌口服免疫疗法：可信吗？系统综述。

背景：幽门螺杆菌（Helicobacter pylori，H. pylori）是一种杆状、革兰氏阴性、嗜微酵母菌，可通过革兰氏染色鉴定。幽门螺杆菌与癌症的关系非常密切，因为大约 80% 的胃癌和 5.5% 的恶性癌症都与幽门螺杆菌有关。幽门螺杆菌有两种治疗方法，但近 40% 的患者对第一种治疗方法无效。最近的试验将口服免疫疗法作为一种新的治疗方法进行了研究。本系统综述的目的是在人体研究中调查口服免疫疗法对幽门螺杆菌根除率的潜在影响：本系统综述根据 PRISMA 指南进行。我们搜索了在线数据库，包括 Scopus、PubMed 和 Web of Science (ISI)。我们的搜索策略仅限于使用口服免疫疗法治疗幽门螺杆菌的英文文章和关于人类的研究：不同数据库中的主要研究记录总数为 2775 条。去除重复文章（870 篇）后，我们排除了 1829 篇文章，原因包括非人类研究、与我们的研究目标不相关、非英语语言或缺乏信息。在剩余的 76 篇文章中，只有 7 篇提供了足够的信息，其余均被排除。这些研究被分为两组：使用牛抗体的研究和使用免疫球蛋白 Y 根除幽门螺杆菌的研究：结论：在免疫球蛋白 Y 组中，四项研究中有三项表明，使用免疫球蛋白 Y 治疗幽门螺杆菌感染效果显著。然而，使用牛抗体治疗幽门螺杆菌感染组的结果各不相同，三项研究中有两项认为牛抗体治疗效果不明显。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Helicobacter 医学-微生物学

CiteScore

8.40

自引率

9.10%

发文量

审稿时长

2 months

期刊介绍： Helicobacter is edited by Professor David Y Graham. The editorial and peer review process is an independent process. Whenever there is a conflict of interest, the editor and editorial board will declare their interests and affiliations. Helicobacter recognises the critical role that has been established for Helicobacter pylori in peptic ulcer, gastric adenocarcinoma, and primary gastric lymphoma. As new helicobacter species are now regularly being discovered, Helicobacter covers the entire range of helicobacter research, increasing communication among the fields of gastroenterology; microbiology; vaccine development; laboratory animal science.